Deutsche Bank bearish on Lundbeck as Rexulti faces mounting headwinds

Deutsche Bank downgraded Lundbeck to sell from hold and cut its price target to DKK36 from DKK40, implying 18% downside from the DKK44.66 prior close. The bank forecasts low-single-digit annual sales declines in 2026-30 as Rexulti, about 25% of revenue, faces Auvelity competition, an IRA-driven U.S. price cut in 2028 and a patent cliff in 2029. Although first-half 2026 revenue grew 16% at constant exchange rates, underlying growth slowed to 13% from 21% in Q1, and Deutsche Bank said pipeline upside, including the Q4 Phase 3 bexicaserin readout, does not offset Rexulti erosion.

Analysis

HLUN.B now faces a valuation regime change: the market is likely to look through current growth and discount the durability of its largest earnings stream. The key issue is not the eventual loss of exclusivity alone, but the sequencing of competitive pressure, government pricing exposure and then generic risk, which compresses the period during which pipeline assets can fund replacement earnings. This raises the probability that management is pushed toward another acquisition before internally generated cash flows weaken, a scenario that would likely be penalized given the Longboard deal has already increased execution scrutiny.

The A-to-B exchange is a near-term technical overhang rather than economic dilution, but it can matter materially for a relatively concentrated shareholder base: additional tradable B-share supply may reduce scarcity support and make negative fundamental revisions transmit more efficiently into the price. The Q4 bexicaserin readout is therefore asymmetric for the equity. Positive data may produce a sharp relief rally, but unless it changes probability-weighted peak sales materially above consensus, it does not solve the multi-year earnings-replacement gap; negative or equivocal data would remove the principal near-term offset to the deteriorating franchise outlook.

Consensus may be underestimating the extent to which the stock can de-rate before reported sales turn negative, as investors typically capitalize a patent-exposed CNS franchise on forward visibility rather than trailing growth. Conversely, the bearish case becomes crowded if the B-share supply event drives shares toward the mid-DKK30s before the clinical catalyst: at that level, the prospective downside is increasingly dependent on disappointing data or a lower 2027-28 earnings guide, rather than merely the already-identified patent and pricing pressures. AXSM is an indirect relative beneficiary if Auvelity continues taking share, although its own valuation and execution risk make it unsuitable as a clean standalone hedge.

Key Decisions for Investors

• Initiate a tactical short HLUN.B on rallies toward DKK44-45 or after the exchange-offer window, targeting DKK36-38 over 1-3 months. Risk is a clearly positive bexicaserin readout or 2027 guidance that demonstrates pipeline contribution sufficient to stabilize medium-term revenue; cover on a sustained break above DKK47.5.
• For mandates able to trade Copenhagen-listed options, prefer a defined-risk Q4/Q1 put structure rather than an oversized outright short ahead of the Phase 3 catalyst. Do not execute unless open interest and implied volatility support efficient pricing; clinical binary risk makes unrestricted short exposure unattractive into the readout.
• Use HLUN.B/European pharma peers as a relative-value short rather than a broad healthcare beta call: short HLUN.B against a diversified European pharma basket or ETF proxy over 3-6 months. The thesis is earnings-duration compression and incremental share supply, not a sector-wide demand shock.
• Set an event alert for the Phase 3 data and the first 2027 revenue/earnings framework. Upgrade the short only if data are non-differentiated or management cannot articulate probability-weighted peak sales that offset the post-2028 franchise erosion; reduce exposure if guidance implies a credible flat-to-growing 2028-30 revenue base.